Furthermore, these studies are consistent with the possibility that the 46% of advanced human prostate cancer tumors that failed to show an increase in Perlecan protein levels over normal tissue may have progressed to a metastatic state through production of a more efficient form of highly sulfated Perlecan due to upregulation of 2OST expression. This evidence concerns the gene HS2ST1 and prostate carcinoma.